Gilead Sciences (GILD) announced Friday that the FDA approved its antibody-drug conjugate Trodelvy for adult patients with HR+/HER2- metastatic breast cancer. R...

5ShareSaveComments(2)Follow us on Google for the latest stock newsFollow Seeking Alpha on Google for the latest stock news Justin Sullivan/Getty Images News

Gilead Sciences (NASDAQ:GILD) announced Friday that the FDA approved its antibody-drug conjugate Trodelvy as a late-line option for certain adult patients with HR+/HER2- metastatic breast cancer.

While Trodelvy is already indicated in the U.S. for less

Източник: seekingalpha.com

Тази статия е автоматично импортирана от външен източник. За оригиналното съдържание на пълната статия, моля посетете източника.

Gilead wins FDA nod for Trodelvy in HR+/HER2 breast cancer (NASDAQ:GILD)

Свързани статии

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Clinical potential and challenges of spatially profiling tumor-infiltrating lymphocytes in early-stage breast cancer

Нужна ви е консултация?